Requesting assistance with filling in the areas highlighted in yellow. I can also provide the abgenix case study associated with this spreadsheet

Abgenix and the Xenomouse Alliance Economics Pharmacol Proposal Sales in Pharmac Probability Minimum SM Maximum $M Overall Clinical Pharmacol Abgenix Probability (only Risk Likelihood Year $M: Payment (they will Succes rates Revenue in Abgenix receive Royalty (%) Royalty in (they will payments (All payments Expected $ Adjusted in of Approva Exhibit 3 | in $M (rNPV) SM $M receive Royalty) 100% egardless of (Weighted Ave) $M rNPV from Ph1 fo payment) certain) probabilities) rNPV Sign o Phase II Phase II o Phase III Phase III FDA/Launch Revenue 20 Revenue 70 Revenue 135 Revenue 250 Revenue 10 330 Revenue 450 Revenue 540 Revenue 620 Revenue 700 Revenue 15 700 3, 815 o of o NPV Analysis Rate Min $ Max $ Expt. $ INPV $ 0% $0.0 $0.00 $0.00 5% $0.0 $0.00 $0.00 10% $0.00 $0.00 $0.00 15% $0.00 $0.00 $0.00 20% $0.00 $0.00 $0.00 Abgenix and the Xenomouse Alliance Economics Biopart Drug Minimum in Sales in BioPart Probability (they will Clinical Revenue in Abgenix Abgenix Probability Partnership Year Payment $M (20% Abgenix $M (only $M: Exhibit 3 in $M receive Succes rates (rNPV) less than Royalty (%) Royalty in ( they will Costs in $M Portion (%) |Abgenix Portion in Probability payments SM payment) receive royalty) (35% COGS) 100% Exhibit 3) certain) Sign Phase II Phase II Phase III Phase III FDA/Launch Revenue 20 Revenue 70 Revenue 135 Revenue 250 Revenue 330 Revenue 450 Revenue 540 Revenue 13 620 Revenue 14 700 Revenue 15 700 3,815 o of NPV Analysis Rate Min $ Max $ 0% $0.00 $0.00 5% $0.00 $0.00 10% $0.00 $0.00 15% $0.00 $0.00 20% $0.00 $0.00 Abgenix and the Xenomouse Alliance Economics DIY Drug Minimum Overall Sales in Addition Probability (they will pay Clinical Maximum $M Revenue in Probability Abgenix M(only Risk Likelihood Year $M: Upfront Succes rates $M (35% (they will Developmen Probability payments (All payments Expected $M Exhibit 3 Costs additional (rNPV) less than receive Costs in $M 100% regardless of (Weighted Ave) Adjusted SM of Approval costs) revenue) (40% COGS probabilities) INPV from Ph1 for Exhibit 3) certain) rNPV Sign 0 0 Phase II Phase II Phase III 0 0 Phase III FDA/Launch Revenue 20 Revenue 70 Revenue 135 Revenue 250 Revenue 10 330 Revenue 450 Revenue 540 Revenue 13 620 Revenue 14 700 Revenue 15 700 3.815 0 0 NPV Analysis Min $ Max $ Expt. $ rNPV Rate Min $ Max $ Expt. S INPV $ Pharmacol 0% $0.00 $0.00 $0.00 Biopart ooo 5% $0.00 $0.00 $0.00 DIY ol 10% $0.00 $0.00 $0.00 15% $0.00 $0.00 $0.00 20% $0.00 $0.00 $0.00 Create PDF